Literature DB >> 1137561

[The effect of intravenous infusion of glucagon on the contractility of the left ventricular myocardum in man (author's transl)].

R Jesse, K W Schneider, P Deeg.   

Abstract

In the cases of 10 cardially healthy humans and 5 patients with heart disease, the left ventricular pressure as well as different parameters of contractility - deduced from the pressure curve and its first derivative - were determined by a catheter-tip manometer (Statham SF - 1). In particular the following values were concerned: dP/dtmax,-dP/dtmaxDP, the maximal calculated shortening velocity of the contractile elements according to the 2-component heart muscle model (VCEmaxTP) as well as with the Maxwell model (VCEmaxDP) and finally the (extrapolated) maximum shortening velocity (Vmax) under a fictive zero load. The examinations were carried out before and during a 10-minute infusion of 60 mg/kg glucagon and 10 minutes after completing the infusion. Besides glucagon also digoxin, etilefrin-HCl-1) and orciprenaline-2) were delivered and the same measurements were performed as with glucagon. A definite statement about the priority of any one of the named indices of contractility is rendered more difficult, because the enddiastolic pressure does not change substantially with glucagon. An unequivocal demarcation of frequency and pressure effects and of inotropic mechanisms as just as impossible, because, with the exception of VmaxDP, all parameters react quantitatively and qualitatively in an equal manner. On the basis of VmaxTP the result of glucagon is only a slight increase in the myocardial contractile capability, which would hardley suffice for the treatment of patients, who do not respond to digitalis. The decline of VmaxDP under glucagon cannot be explained. Under digitalis, etilefrin and orciprenaline, a similar dissociation of values for the maximum shortening velocity according to the 2- or 3-component-model of the heart muscle cannot be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1137561     DOI: 10.1007/bf01905622

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  9 in total

Review 1.  [Muscle physiology as a basis for the evaluation of heart capacity].

Authors:  R Jacob; R Gülch; G Kissling; U Raff
Journal:  Z Gesamte Inn Med       Date:  1973-01-01

2.  [The reliability of different indices of myocardial contractility in the heart of closed-chest-dogs].

Authors:  U Raff; W Stauber; G Kissling
Journal:  Basic Res Cardiol       Date:  1974 Jan-Feb       Impact factor: 17.165

3.  Cardiovascular effects of glucagon in man.

Authors:  W W Parmley; G Glick; E H Sonnenblick
Journal:  N Engl J Med       Date:  1968-07-04       Impact factor: 91.245

4.  [Influence of glucagon on hemodynamics of the human heart following beta-receptor blockade].

Authors:  H Avenhaus; B Lüderitz; E Nordeck
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1971

5.  Cardiovascular effects of glucagon in man.

Authors:  S W Klein; J E Morch; W A Mahon
Journal:  Can Med Assoc J       Date:  1968-06-22       Impact factor: 8.262

6.  Cardiovascular effects of glucagon in man.

Authors:  J W Linhart; S S Barold; L S Cohen; F J Hildner; P Samet
Journal:  Am J Cardiol       Date:  1968-11       Impact factor: 2.778

7.  Effects of glucagon on myocardial metabolism in patients with and without coronary artery disease.

Authors:  M G Bourassa; J Eibar; L Campeau
Journal:  Circulation       Date:  1970-07       Impact factor: 29.690

8.  Hemodynamic effects of glucagon in patients with heart disease.

Authors:  J F Williams; R H Childress; J N Chip; J F Border
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

9.  Hemodynamic effects of glucagon in patients following prosthetic valve replacement.

Authors:  W W Parmley; J M Matloff; E H Sonnenblick
Journal:  Circulation       Date:  1969-05       Impact factor: 29.690

  9 in total
  2 in total

1.  Glucagon Increases Beating Rate but Not Contractility in Rat Right Atrium. Comparison with Isoproterenol.

Authors:  Beatriz Merino; Ivan Quesada; Jesús Hernández-Cascales
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

2.  Does glucagon have a positive inotropic effect in the human heart?

Authors:  Jesus Hernández-Cascales
Journal:  Cardiovasc Diabetol       Date:  2018-11-27       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.